<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): February 19, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>HEARTWARE INTERNATIONAL, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>000-52595</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>26-3636023</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>205 Newbury Street, Suite 101<BR>Framingham, MA<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>01701</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>508.739.0950</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>Item&nbsp;7.01 Regulation&nbsp;FD Disclosure</B>


<P align="left" style="font-size: 10pt">HeartWare International, Inc. (ASX:HIN) announced today (February&nbsp;20, 2009 Australian Eastern Standard Time), via an
Australian Securities Exchange (&#147;ASX&#148;) announcement, that its application to list its common shares on the NASDAQ
Global Market (NASDAQ)&nbsp;has been approved. Trading will commence at 10:00am Eastern Standard Time on February&nbsp;24, 2009.


<P align="left" style="font-size: 10pt">Following the listing on NASDAQ, HeartWare will maintain dual listings, with common shares trading on NASDAQ under the
symbol <B>HTWR </B>and Chess Depository Interests (CDIs) continuing to trade on the Australian Securities Exchange (ASX)&nbsp;under
the symbol <B>HIN</B>.


<P align="left" style="font-size: 10pt">As previously advised, security holders are able to convert between NASDAQ listed common shares and ASX listed CDIs on
the basis that each common share can be converted into 35 CDIs, and vice versa. Security holders wishing to convert
their holdings from one form of security to the other can do so by contacting the company&#146;s share register
(Computershare).


<P align="left" style="font-size: 10pt">Given the ability for holders to exchange between HTWR and HIN, it is expected that the trading prices of the two forms
of security will broadly track one another. That is, it is expected that the trading price of HTWR securities on
NASDAQ should be approximately 35 times the trading price of HIN securities on ASX after allowing for the USD/AUD
exchange rate.


<P align="left" style="font-size: 10pt"><B>U.S. Market Makers</B>


<P align="left" style="font-size: 10pt">In order to establish a trading market in the United States following the NASDAQ listing, J.P. Morgan, Cannaccord Adams
and Lazard Capital Management will serve as HeartWare&#146;s initial market makers. Analyst coverage has already commenced,
with Lazard Capital Management, Summer Street Research Partners and Pacific Growth Equities having initiated research
in recent months.


<P align="left" style="font-size: 10pt"><B>Capital Structure</B>


<P align="left" style="font-size: 10pt">HeartWare currently has 8,866,702 shares of common stock on issue. These are represented by 309,092,210 CDIs (being a
ratio of one share of common stock to 35 CDIs). Following the listing on NASDAQ, it is expected that a number of
investors, particularly those based in the United States, will migrate their holdings from Australia to the United
States by exchanging their CDIs for common stock.


<P align="left" style="font-size: 10pt">Approximately 80% of HeartWare&#146;s shares are held by investors located in the United States. The Company&#146;s four largest
shareholders, Apple Tree Partners, Mr.&nbsp;Muneer Satter, Fidelity Investments and Deephaven Capital Management, together
account for approximately 60% of HeartWare&#146;s issued capital. The remaining 20% of US-owned stock is held by a
relatively small number of primarily specialist healthcare funds.


<P align="left" style="font-size: 10pt">A copy of the complete ASX announcement is attached.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>


<P align="left" style="font-size: 10pt">Exhibit&nbsp;99.1 HeartWare International, Inc. ASX announcement, dated February&nbsp;20, 2009

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>SIGNATURES</B>


<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">HeartWare International, Inc.</TD>
</TR>

<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: February&nbsp;19, 2009
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ David McIntyre</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD nowrap colspan="2" align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: David McIntyre</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Chief Financial Officer and
Chief Operating Officer</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 10pt">

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>EXHIBIT INDEX</B>


<P align="left" style="font-size: 10pt">Exhibit&nbsp;99.1 HeartWare International, Inc. ASX announcement, dated February&nbsp;20, 2009


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4




</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c81418e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 10787}]
{"company-data": {"conformed-name": "HeartWare International, Inc.", "cik": "0001389072", "assigned-sic": "3841", "irs-number": "980498958", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52595", "film-number": "09622392"}, "business-address": {"street1": "14000 NW 57TH COURT", "city": "MIAMI LAKES", "state": "FL", "zip": "33014", "phone": "508-739-0841"}, "mail-address": {"street1": "205 NEWBURY STREET", "street2": "SUITE 101", "city": "FRAMINGHAM", "state": "MA", "zip": "01701"}, "former-company": {"former-conformed-name": "HeartWare LTD", "date-changed": "20070206"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 19, 2009
HEARTWARE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-52595
26-3636023
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
205 Newbury Street, Suite 101
Framingham, MA
01701
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
508.739.0950
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
HeartWare International, Inc. (ASX:HIN) announced today (February 20, 2009 Australian Eastern Standard Time), via an
Australian Securities Exchange ("ASX") announcement, that its application to list its common shares on the NASDAQ
Global Market (NASDAQ) has been approved. Trading will commence at 10:00am Eastern Standard Time on February 24, 2009.
Following the listing on NASDAQ, HeartWare will maintain dual listings, with common shares trading on NASDAQ under the
symbol
HTWR
and Chess Depository Interests (CDIs) continuing to trade on the Australian Securities Exchange (ASX) under
the symbol
HIN
.
As previously advised, security holders are able to convert between NASDAQ listed common shares and ASX listed CDIs on
the basis that each common share can be converted into 35 CDIs, and vice versa. Security holders wishing to convert
their holdings from one form of security to the other can do so by contacting the company's share register
(Computershare).
Given the ability for holders to exchange between HTWR and HIN, it is expected that the trading prices of the two forms
of security will broadly track one another. That is, it is expected that the trading price of HTWR securities on
NASDAQ should be approximately 35 times the trading price of HIN securities on ASX after allowing for the USD/AUD
exchange rate.
U.S. Market Makers
In order to establish a trading market in the United States following the NASDAQ listing, J.P. Morgan, Cannaccord Adams
and Lazard Capital Management will serve as HeartWare's initial market makers. Analyst coverage has already commenced,
with Lazard Capital Management, Summer Street Research Partners and Pacific Growth Equities having initiated research
in recent months.
Capital Structure
HeartWare currently has 8,866,702 shares of common stock on issue. These are represented by 309,092,210 CDIs (being a
ratio of one share of common stock to 35 CDIs). Following the listing on NASDAQ, it is expected that a number of
investors, particularly those based in the United States, will migrate their holdings from Australia to the United
States by exchanging their CDIs for common stock.
Approximately 80% of HeartWare's shares are held by investors located in the United States. The Company's four largest
shareholders, Apple Tree Partners, Mr. Muneer Satter, Fidelity Investments and Deephaven Capital Management, together
account for approximately 60% of HeartWare's issued capital. The remaining 20% of US-owned stock is held by a
relatively small number of primarily specialist healthcare funds.
A copy of the complete ASX announcement is attached.
Item 9.01 Financial Statements and Exhibits
Exhibit 99.1 HeartWare International, Inc. ASX announcement, dated February 20, 2009
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
HeartWare International, Inc.
Date: February 19, 2009
By:
/s/ David McIntyre
Name: David McIntyre
Title: Chief Financial Officer and
Chief Operating Officer
EXHIBIT INDEX
Exhibit 99.1 HeartWare International, Inc. ASX announcement, dated February 20, 2009